• Home
  • News
  • Government
  • Business & Finance
  • Entertainment
  • Sports
  • Tech
  • Health
  • About Federal Character
  • Advertise With Us
Federal Character
No Result
View All Result
Federal Character
  • Home
  • News
  • Government
  • Business & Finance
  • Entertainment
  • Sports
  • Tech
  • Health
  • About Federal Character
  • Advertise With Us
No Result
View All Result
Federal Character
No Result
View All Result
Home Health
​Daraxonrasib Trial Gives Pancreatic Cancer Hope

​Daraxonrasib Trial Gives Pancreatic Cancer Hope

Eriki Joan UgunushebyEriki Joan Ugunushe
8 minutes ago
in Health
Reading Time: 2 mins read
A A
0
Facebook ShareWhatsapp ShareX Share

​Patients and oncologists are welcoming encouraging clinical trial news as the daraxonrasib trial gives pancreatic cancer hope against one of the deadliest and hardest-to-treat forms of cancer in the world. Updated findings from a clinical trial evaluating the targeted oral pill daraxonrasib alongside chemotherapy in 61 patients with newly diagnosed advanced pancreatic cancer that had spread to other organs were presented Friday in Barcelona at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Across an average follow-up of roughly 18 months, tumors shrank or disappeared in just over 60% of participants, cancer became undetectable on scans in roughly one in 12 patients (about 8%), and tumor growth was halted or controlled in roughly 90% of those treated.

Table of Contents

Toggle
  • ​Targeting KRAS Mutations and Improving One-Year Survival
  • ​Cautious Optimism Ahead of Larger Studies
  • ​My View

​Targeting KRAS Mutations and Improving One-Year Survival

​Pancreatic cancer often goes undetected until it has already spread, leaving roughly half of diagnosed patients dead within three months and giving metastatic cases a dismal five-year survival rate of around 3%. Researchers say daraxonrasib stands out because it works as a KRAS inhibitor, targeting mutated RAS proteins that drive tumor growth in the vast majority of pancreatic cancers, mutations once widely considered “undruggable”.

​Daraxonrasib Trial Gives Pancreatic Cancer Hope

About 76.6% of patients on the treatment were alive after one year, compared with historical averages of roughly 40% to 45% for standard chemotherapy alone. Tumours shrank or disappeared in about 60.7% of trial participants, with 8.2% showing no detectable disease on scans and roughly 90.2% achieving disease control over a median follow-up of 18.3 months. Because KRAS and related mutations also play a role in several other cancers, including certain lung and ovarian cancers, oncologists note the approach could eventually open doors to wider research.

​Cautious Optimism Ahead of Larger Studies

​Presenting the results, Dr. Wungki Park of Memorial Sloan Kettering Cancer Center in New York called the findings “the closest to cure” he had seen in metastatic pancreatic cancer, while Cancer Research UK chief executive Michelle Mitchell hailed the advance as the biggest leap forward in decades for the disease. Still, specialists emphasize that the study involved a relatively small group of 61 patients without a direct head-to-head comparison arm in that cohort, meaning larger and longer trials are needed to confirm long-term remission and regulatory approval pathways. Even so, as the daraxonrasib trial gives pancreatic cancer hope, families facing a grim diagnosis see a rare sign of real momentum against a relentless killer.

​My View

​Any genuine step forward against a disease as devastating as pancreatic cancer deserves celebration, especially for families who have spent decades hearing nothing but grim statistics.
​At the same time, promising early trial results should never be turned into hype that misleads patients into thinking a cure is already sitting on pharmacy shelves tomorrow. Rigorous clinical trials exist for a reason: they test whether early shrinkage and survival gains hold up across larger populations and track side effects over time.

​Equally important, once life-extending treatments do clear safety and effectiveness hurdles, healthcare systems must work to make them affordable and reachable rather than locking breakthroughs behind sky-high prices or slow bureaucracy. Hope is strongest when solid science is paired with honest expectations and fair access for every patient who needs it.
​

Tags: ​Daraxonrasib Trialfederal characterForeign NewshealthNewsPancreatic Cancer
Share234SendTweet146
Eriki Joan Ugunushe

Eriki Joan Ugunushe

Eriki Joan Ugunushe is a dedicated news writer and an aspiring entertainment and media lawyer. Graduated from the University of Ibadan, she combines her legal acumen with a passion for writing to craft compelling news stories.Eriki's commitment to effective communication shines through her participation in the Jobberman soft skills training, where she honed her abilities to overcome communication barriers, embrace the email culture, and provide and receive constructive feedback. She has also nurtured her creativity skills, understanding how creativity fosters critical thinking—a valuable asset in both writing and law.

Related Stories

South America Braces for Measles Amid Papal Crowds

South America Braces for Measles Amid Papal Crowds

byEriki Joan Ugunushe
0

If you are in this area, or traveling to that area, watch out for measles, because South America is bracing for measles amid papal crowds as millions of...

U.S. Loses Measles Elimination Status After 26 Years

U.S. Loses Measles Elimination Status After 26 Years

byEriki Joan Ugunushe
0

A major public health milestone achieved at the turn of the century has officially unraveled, as the U.S. loses measles elimination status after 26 years following a surge...

Ebola Crisis: Congo Reports 10,000 Cases Amid Strikes, Attacks on Health Workers

Ebola Crisis: Congo Reports 10,000 Cases Amid Strikes, Attacks on Health Workers

byAyobami Owolabi
0

The Ebola outbreak in the Democratic Republic of Congo has surpassed 10,000 confirmed cases, with nearly half of those infected dying as health authorities struggle to contain the...

Ebola Crisis: Congo Reports 10,000 Cases Amid Strikes, Attacks on Health Workers

Nigeria Confirms First Ebola Case in Abuja as Outbreak Spreads

byFed Editor
0

Nigeria has confirmed an Ebola case in its capital, Abuja, after a woman who arrived from Uganda tested positive for the virus, the health ministry said. The woman...

Next Post
Why GTA VI Feels More Lifelike

​Why GTA VI Feels More Lifelike

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Federal Character

We bring to you precise and factual news.
Towson, Baltimore, Maryland, USA

Recent Posts

  • ​Why GTA VI Feels More Lifelike
  • ​Daraxonrasib Trial Gives Pancreatic Cancer Hope
  • ​Is Florida Still Winnable, or Did Democrats Quit?

Categories

  • Beauty
  • Business & Finance
  • Entertainment
  • Fashion & Lifestyle
  • Food & Nutrition
  • Government
  • Health
  • News
  • Politics
  • Sports
  • Tech

Weekly Newsletter

  • Home
  • About Federal Character
  • Advertise With Us
  • Cookie Policy
  • Sitemap

Copyright © FederalCharacter.com 2026 .

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
  • Government
  • Business & Finance
  • Entertainment
  • Sports
  • Tech
  • Health
  • About Federal Character
  • Advertise With Us

Copyright © FederalCharacter.com 2026 .